ASCENDIS PHARMA A/S - ADR (ASND) Stock Balance Sheet
USA - NASDAQ:ASND - US04351P1012 - ADR
216.56 USD
+12.16 (+5.95%)
220 USD
+3.44 (+1.59%)
| MRQ (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | null | null | null | null | null | |||
| Cash Equivalents | 539.09M | 559.54M | 392.16M | 444.80M | 446.30M | |||
| Cash Due From Banks | null | null | null | null | null | |||
| Investments | null | null | null | null | null | |||
| Net Loans | null | null | null | null | null | |||
| Insurance Receivables | null | null | null | null | null | |||
| Marketable Securities | null | 0 | 7.28M | 290.70M | 235.80M | |||
| Receivables | 147.25M | 177.44M | 55.77M | 25.60M | 23.20M | |||
| Inventories | 302.02M | 295.61M | 208.93M | 130.70M | 75.40M | |||
| Other Current Assets | 29.42M | 28.27M | 38.58M | 31.70M | 25.20M | |||
| Total Current Assets | 1.02B | 1.06B | 702.72M | 923.50M | 805.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 101.76M | 98.71M | 110.63M | 129.10M | 126.00M | |||
| Investments And Advances | 28.30M | 13.57M | 5.69M | 30.40M | 145.90M | |||
| Goodwill | null | 3.50M | 3.50M | 3.50M | 3.50M | |||
| Intangibles | 3.74M | 533.00K | 924.00K | 1.30M | 1.80M | |||
| Other Non-Current Assets | null | null | null | null | null | |||
| Total Non-Current Assets | 136.97M | 118.63M | 122.87M | 166.20M | 279.00M | |||
| TOTAL ASSETS | 1.15B | 1.18B | 825.59M | 1.09B | 1.08B | |||
| LIABILITIES | ||||||||
| Total Deposits | null | null | null | null | null | |||
| Current Liabilities | ||||||||
| Short Term Borrowings | null | null | null | null | null | |||
| Short Term Debt | 56.04M | 33.33M | 14.17M | 0 | 0 | |||
| Current Portion Of LT Debt. | 426.24M | 458.21M | 407.10M | 25.40M | 7.00M | |||
| Accrued Expenses | null | null | null | null | null | |||
| Accounts Payable | 78.60M | 96.39M | 94.57M | 101.00M | 59.40M | |||
| Other Current Liabilities | 425.60M | 319.93M | 220.67M | 44.80M | 33.90M | |||
| Total Current Liabilities | 986.48M | 907.86M | 736.51M | 171.30M | 100.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 331.37M | 365.08M | 223.00M | 483.00M | 98.00M | |||
| Deferred Taxes/Income | 10.28M | 7.26M | 5.83M | null | null | |||
| Other Non-Current Liabilities | 692.00K | 5.00M | 5.95M | 172.20M | 3.00M | |||
| Total Non-Current Liabilities | 342.34M | 377.34M | 234.78M | 655.10M | 100.90M | |||
| TOTAL LIABILITIES | 1.33B | 1.29B | 971.28M | 826.40M | 201.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.70B | -2.56B | -2.28B | -1.86B | -1.21B | |||
| Additional Paid In Capital | null | null | null | null | null | |||
| Minority Interest | null | null | null | null | null | |||
| Common Shares | 2.52B | 2.45B | 2.13B | 2.12B | 2.12B | |||
| Treasury Stock | -80.00K | -113.00K | -146.00K | -100.00K | -21.60M | |||
| Other Shareholders' Equity | -1.26M | 1.78M | 721.00K | 3.50M | 3.80M | |||
| Shares Outstanding | 61.43M | 60.43M | 57.46M | 56.95M | 56.65M | |||
| Tangible Book Value per Share | -2.8822 | -1.8081 | -2.6013 | 4.5192 | 15.4359 | |||
| Total Shareholders' Equity | -174.07M | -105.71M | -145.70M | 263.30M | 883.60M | |||
| TOTAL LIABILITIES AND EQUITY | 1.15B | 1.18B | 825.59M | 1.09B | 1.08B | |||
| Statistics | ||||||||
| Debt/Equity | -2.23 | -3.77 | -1.63 | 1.83 | 0.11 | |||
| Current Ratio | 1.03 | 1.17 | 0.95 | 5.39 | 8.03 | |||
| Return On Assets (ROA) | -20.17% | -32.05% | -58.32% | -53.52% | -35.36% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | -221.49% | -43.41% | |||
All data in EUR , ROIC based on taxRate of 0.21